Radziwonik W, Elert-Dobkowska E, Tomczuk F, Wozniak A, Sobanska A, Stepniak I, Koziorowski D, Zaremba J, Sułek A. C9orf72 hexanucleotide repeat expansion found in suspected spinobulbar muscular atrophy (SBMA).
Neurol Neurochir Pol 2022;
56:276-280. [PMID:
35661131 DOI:
10.5603/pjnns.a2022.0039]
[Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Revised: 04/07/2022] [Accepted: 04/07/2022] [Indexed: 11/25/2022]
Abstract
INTRODUCTION
The expansion of a hexanucleotide GGGGCC repeat (G4C2) in the C9orf72 locus is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). In addition, C9orf72 expansion has also been detected in patients with a clinical manifestation of Parkinson's Disease (PD), Alzheimer's Disease (AD), Huntington's Disease (HD), and ataxic disorders.
MATERIAL AND METHODS
A total of 1,387 patients with clinically suspected ALS, HD or spinal and bulbar muscular atrophy (SBMA) were enrolled, and the prevalence of C9orf72 expansions was estimated.
RESULTS
The hexanucleotide expansion accounted for 3.7% of the ALS patients, 0.2% of the HD suspected patients with excluded HTT mutation, and 1.3% of the suspected SBMA patients with excluded mutation in AR gene.
CONCLUSIONS
This is the first report revealing the presence of C9orf72 expansion in patients with a suspected SBMA diagnosis. Consequently, we advise testing for C9orf72 expansion in patients presenting with the SBMA phenotype and a genetically unsolved diagnosis.
Collapse